Considering that most of the MDS patients with SF3B1 mutation presented a favorable clinical outcome and low risk of progression to leukemia [37,40,46], it may be assumed that SF3B1 gene mutations are less frequent in cases with MDS transformation into AML than in MDS cases. This evidence concerns the gene SF3B1 and leukemia.